Yale-New Haven Hospital
- Type
- Teaching hospital
- Where
- New Haven, CT
- Medicare CCN
- 070022
- Received
- $1,067,772 in 198 records, 2021 ($181,880 general, $885,892 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Yale New Haven Hospital, Inc. Fuzzy (name and state)
- Business registration: Yale New Haven Hospital, Inc. Fuzzy (name and state)
- Nonprofit contractor: YALE NEW HAVEN HOSPITAL Fuzzy (name and state)
- Plan sponsor: YALE-NEW HAVEN HOSPITAL, INC. Fuzzy (name and state)
- Federal award recipient: YALE NEW HAVEN HOSPITAL, INC. Fuzzy (name and state)
- Lobbying client: YALE NEW HAVEN HOSPITAL Fuzzy (name and state)
- Lobbying client: YALE-NEW HAVEN HOSPITAL, INC. Fuzzy (name and state)
- Lobbying registrant: YALE-NEW HAVEN HOSPITAL Fuzzy (name and state)
- Nonprofit: YALE NEW HAVEN HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 65 | $181,880 |
| 2021 | Research payment | 133 | $885,892 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 133 | $885,892 |
| Space rental or facility fees (teaching hospital only) | 6 | $50,000 |
| Gift | 12 | $45,139 |
| Debt forgiveness | 13 | $23,558 |
| Long term medical supply or device loan | 10 | $21,081 |
| Grant | 5 | $21,071 |
| Education | 1 | $10,000 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 2 | $8,000 |
| Charitable Contribution | 16 | $3,027 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | Omeros Corporation | $32,874 | Research payment | Cash or cash equivalent | An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients | 2021 | |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $6,750 | Research payment | Cash or cash equivalent | Yale New Haven Hosp Constable Neuro Clinical MR | 2021 | |
| 2021-12-31 | Edwards Lifesciences Corporation | $3,471 | Long term medical supply or device loan | In-kind items and services | HemoSphere Device, Hemodynamic Monitoring | 2021 | |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $675 | Research payment | Cash or cash equivalent | YaleNewHavenHosp2019IPR925TurkBrowne | 2021 | |
| 2021-12-31 | Edwards Lifesciences Corporation | $364 | Long term medical supply or device loan | In-kind items and services | HemoSphere Device, Hemodynamic Monitoring | 2021 | |
| 2021-12-31 | Stryker Corporation | $335 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-12-31 | Edwards Lifesciences Corporation | $283 | Long term medical supply or device loan | In-kind items and services | HemoSphere Device, Hemodynamic Monitoring | 2021 | |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $149 | Research payment | Cash or cash equivalent | Yale2021MRIPR022IPR023IPR024Mahajan | 2021 | |
| 2021-12-31 | Medline Industries LP | $74 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-12-22 | Sage Therapeutics, LLC | $4,160 | Research payment | Cash or cash equivalent | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC | 2021 | |
| 2021-12-22 | SEAGEN INC. | $1,500 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2021 |
| 2021-12-22 | SEAGEN INC. | $750 | Research payment | Cash or cash equivalent | A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | 2021 | |
| 2021-12-17 | Orthofix Medical, Inc. | $468 | Research payment | Cash or cash equivalent | M6-C Device, Prosthesis, Intervertebral Disc | M6-C Post Approval Study (PAS)- CA-C004 | 2021 |
| 2021-12-15 | SEAGEN INC. | $9,953 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2021 |
| 2021-12-14 | SERVIER PHARMACEUTICALS LLC | $390 | Research payment | Cash or cash equivalent | STUDY OF AG-270 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA WITH MTAP LOSS | 2021 | |
| 2021-12-13 | SERVIER PHARMACEUTICALS LLC | $1,128 | Research payment | Cash or cash equivalent | STUDY OF AG-270 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA WITH MTAP LOSS | 2021 | |
| 2021-12-08 | SEAGEN INC. | $4,044 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-12-08 | Indivior Inc. | $641 | Research payment | In-kind items and services | SUBLOCADE Drug, OUD | COORDINATING OPIOID USE TREATMENT THROUGH MEDICAL MANAGEMENT WITH INFECTION TREATMENT (PROJECT COMMIT) | 2021 |
| 2021-12-06 | Indivior Inc. | $961 | Research payment | In-kind items and services | SUBLOCADE Drug, OUD | LONG-ACTING BUPRENORPHINE VS. NALTREXONE OPIOID TREATMENTS IN CJS-INVOLVED ADULTS | 2021 |
| 2021-12-02 | SEAGEN INC. | $9,204 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2021 |
| 2021-12-01 | Cardiovascular Systems Inc. | $56 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2021 |
| 2021-11-23 | SEAGEN INC. | $2,162 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-11-23 | SEAGEN INC. | $1,500 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-11-17 | SEAGEN INC. | $780 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2021 |
| 2021-11-10 | SEAGEN INC. | $780 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2021 |
| 2021-11-10 | SEAGEN INC. | $390 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2021 |
| 2021-11-04 | Heron Therapeutics, Inc. | $5,730 | Research payment | Cash or cash equivalent | Drug | Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1) | 2021 |
| 2021-10-26 | CARDIVA MEDICAL, INC. | $45,000 | Research payment | Cash or cash equivalent | Cardiva VASCADE 5F VCS Device, Devices | VASCADE Device Outcomes | 2021 |
| 2021-10-20 | Eisai Inc. | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Fycompa Drug, Neurology | 2021 | |
| 2021-10-20 | SEAGEN INC. | $750 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2021 |
| 2021-10-19 | Orthofix Medical, Inc. | $400 | Research payment | Cash or cash equivalent | M6-C Device, Prosthesis, Intervertebral Disc | M6-C Post Approval Study (PAS)- CA-C004 | 2021 |
| 2021-10-13 | SEAGEN INC. | $4,092 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-10-13 | SEAGEN INC. | $3,702 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2021 |
| 2021-10-13 | SEAGEN INC. | $1,580 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2021 |
| 2021-10-13 | SEAGEN INC. | $1,050 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2021 |
| 2021-10-11 | SEAGEN INC. | $7,500 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2021 | |
| 2021-10-11 | SEAGEN INC. | $4,000 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2021 | |
| 2021-10-11 | SEAGEN INC. | $2,929 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2021 | |
| 2021-10-11 | SEAGEN INC. | $1,170 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2021 | |
| 2021-10-11 | SEAGEN INC. | $937 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2021 | |
| 2021-10-11 | SEAGEN INC. | $550 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2021 | |
| 2021-10-07 | Heron Therapeutics, Inc. | $2,660 | Research payment | Cash or cash equivalent | Drug | Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1) | 2021 |
| 2021-10-06 | SEAGEN INC. | $9,350 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2021 |
| 2021-10-06 | SEAGEN INC. | $9,223 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2021 |
| 2021-10-06 | SEAGEN INC. | $2,598 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-10-04 | AstraZeneca Pharmaceuticals LP | $31 | Charitable Contribution | Cash or cash equivalent | 2021 | ||
| 2021-09-29 | Mindray DS USA, Inc. | $1,020 | Long term medical supply or device loan | Cash or cash equivalent | AG Module(O2/package/accessory) Device, MONITORING EQUIPMENT | 2021 | |
| 2021-09-29 | Mindray DS USA, Inc. | $1,020 | Long term medical supply or device loan | Cash or cash equivalent | AG Module(O2/package/accessory) Device, MONITORING EQUIPMENT | 2021 | |
| 2021-09-29 | Bio-Rad Laboratories, Inc. | $326 | Debt forgiveness | Cash or cash equivalent | Electrophoresis Reagents Device, Electrophoresis | 2021 | |
| 2021-09-29 | Mindray DS USA, Inc. | $102 | Long term medical supply or device loan | Cash or cash equivalent | BeneLink Module package Device, MONITORING EQUIPMENT | 2021 | |
| 2021-09-29 | Mindray DS USA, Inc. | $100 | Long term medical supply or device loan | Cash or cash equivalent | BeneLink Module package Device, MONITORING EQUIPMENT | 2021 | |
| 2021-09-29 | Mindray DS USA, Inc. | $100 | Long term medical supply or device loan | Cash or cash equivalent | BeneLink Module package Device, MONITORING EQUIPMENT | 2021 | |
| 2021-09-28 | Orthofix Medical, Inc. | $1,500 | Research payment | Cash or cash equivalent | M6-C Device, Prosthesis, Intervertebral Disc | Restore CLINICAL TRIAL CA-C002 (M6 IDE) | 2021 |
| 2021-09-23 | Sage Therapeutics, LLC | $250 | Research payment | Cash or cash equivalent | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC | 2021 | |
| 2021-09-22 | SEAGEN INC. | $18,064 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2021 |
| 2021-09-22 | ZOLL Circulation Inc | $5,735 | Gift | Cash or cash equivalent | Temperature Management System Device, Temperature Management | 2021 | |
| 2021-09-22 | ZOLL Circulation Inc | $5,220 | Gift | Cash or cash equivalent | Temperature Management System Device, Temperature Management | 2021 | |
| 2021-09-22 | ZOLL Circulation Inc | $2,090 | Gift | Cash or cash equivalent | Temperature Management System Device, Temperature Management | 2021 | |
| 2021-09-21 | SEAGEN INC. | $1,249 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-09-21 | SEAGEN INC. | $500 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-09-21 | SEAGEN INC. | $500 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-09-20 | Johnson & Johnson Health Care Systems Inc. | $2,256 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-09-20 | SEAGEN INC. | $1,500 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2021 | |
| 2021-09-16 | ZOLL Circulation Inc | $4,010 | Gift | Cash or cash equivalent | Temperature Management System Device, Temperature Management | 2021 | |
| 2021-09-16 | ZOLL Circulation Inc | $4,010 | Gift | Cash or cash equivalent | Temperature Management System Device, Temperature Management | 2021 | |
| 2021-09-16 | ZOLL Circulation Inc | $4,010 | Gift | Cash or cash equivalent | Temperature Management System Device, Temperature Management | 2021 | |
| 2021-09-16 | ZOLL Circulation Inc | $4,010 | Gift | Cash or cash equivalent | Temperature Management System Device, Temperature Management | 2021 | |
| 2021-09-16 | ZOLL Circulation Inc | $4,010 | Gift | Cash or cash equivalent | Temperature Management System Device, Temperature Management | 2021 | |
| 2021-09-16 | ZOLL Circulation Inc | $4,010 | Gift | Cash or cash equivalent | Temperature Management System Device, Temperature Management | 2021 | |
| 2021-09-16 | ZOLL Circulation Inc | $4,010 | Gift | Cash or cash equivalent | Temperature Management System Device, Temperature Management | 2021 | |
| 2021-09-16 | ZOLL Circulation Inc | $4,010 | Gift | Cash or cash equivalent | Temperature Management System Device, Temperature Management | 2021 | |
| 2021-09-15 | Siemens Medical Solutions USA, Inc. | $700 | Research payment | Cash or cash equivalent | YaleNewHavenHosp2016MRIPR1023Huber | 2021 | |
| 2021-09-13 | AstraZeneca Pharmaceuticals LP | $52 | Charitable Contribution | Cash or cash equivalent | 2021 | ||
| 2021-09-07 | E.R. Squibb & Sons, L.L.C. | $2,250 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-09-07 | E.R. Squibb & Sons, L.L.C. | $200 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-09-01 | AstraZeneca Pharmaceuticals LP | $139 | Charitable Contribution | Cash or cash equivalent | 2021 | ||
| 2021-08-31 | AstraZeneca Pharmaceuticals LP | $26 | Charitable Contribution | Cash or cash equivalent | 2021 | ||
| 2021-08-30 | Indivior Inc. | $192 | Research payment | In-kind items and services | SUBLOCADE Drug, OUD | COORDINATING OPIOID USE TREATMENT THROUGH MEDICAL MANAGEMENT WITH INFECTION TREATMENT (PROJECT COMMIT) | 2021 |
| 2021-08-30 | AstraZeneca Pharmaceuticals LP | $104 | Charitable Contribution | Cash or cash equivalent | 2021 | ||
| 2021-08-27 | AstraZeneca Pharmaceuticals LP | $139 | Charitable Contribution | Cash or cash equivalent | 2021 | ||
| 2021-08-25 | GE HEALTHCARE | $283 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-08-24 | Johnson & Johnson Health Care Systems Inc. | $5,328 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-08-24 | Johnson & Johnson Health Care Systems Inc. | $4,950 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-08-24 | Johnson & Johnson Health Care Systems Inc. | $3,108 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-08-18 | SEAGEN INC. | $4,833 | Research payment | Cash or cash equivalent | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2021 | |
| 2021-08-18 | SEAGEN INC. | $1,800 | Research payment | Cash or cash equivalent | A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | 2021 | |
| 2021-08-17 | E.R. Squibb & Sons, L.L.C. | $15,000 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-08-16 | SEAGEN INC. | $58,574 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2021 | |
| 2021-08-14 | Conformis, Inc. | $14,300 | Research payment | Cash or cash equivalent | iTotal CR Device, ORTHOPAEDIC KNEE IMPLANTS | iTotal 12-005 | 2021 |
| 2021-08-14 | Conformis, Inc. | $2,439 | Research payment | Cash or cash equivalent | iTotal CR Device, ORTHOPAEDIC KNEE IMPLANTS | iTotal 12-005 | 2021 |
| 2021-08-12 | SEAGEN INC. | $9,870 | Research payment | In-kind items and services | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2021 |
| 2021-08-12 | SEAGEN INC. | $9,864 | Research payment | In-kind items and services | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2021 |
| 2021-08-12 | Heron Therapeutics, Inc. | $1,500 | Research payment | Cash or cash equivalent | Drug | Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1) | 2021 |
| 2021-08-11 | SEAGEN INC. | $18,262 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2021 |
| 2021-08-11 | SEAGEN INC. | $9,953 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2021 |
| 2021-08-11 | SEAGEN INC. | $6,253 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2021 |
| 2021-08-11 | Amgen Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-08-11 | AstraZeneca Pharmaceuticals LP | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2021 | |
| 2021-08-11 | SEAGEN INC. | $248 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2021 |
| 2021-08-11 | Boston Scientific Corporation | $50 | Charitable Contribution | Cash or cash equivalent | 2021 | ||
| 2021-08-10 | AstraZeneca Pharmaceuticals LP | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TAGRISSO Drug, Oncology | 2021 | |
| 2021-08-10 | AstraZeneca Pharmaceuticals LP | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | IMFINZI Biological, Oncology | 2021 | |
| 2021-08-06 | SEAGEN INC. | $10,000 | Education | Cash or cash equivalent | ADCETRIS Biological, Oncology | 2021 | |
| 2021-08-01 | Medical Device Business Services, Inc. | $3,021 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-07-27 | Henry Schein, Inc. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-07-27 | SERVIER PHARMACEUTICALS LLC | $2,750 | Research payment | Cash or cash equivalent | STUDY OF AG-270 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA WITH MTAP LOSS | 2021 | |
| 2021-07-27 | SERVIER PHARMACEUTICALS LLC | $1,653 | Research payment | Cash or cash equivalent | STUDY OF AG-270 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA WITH MTAP LOSS | 2021 | |
| 2021-07-27 | SERVIER PHARMACEUTICALS LLC | $390 | Research payment | Cash or cash equivalent | STUDY OF AG-270 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA WITH MTAP LOSS | 2021 | |
| 2021-07-26 | SERVIER PHARMACEUTICALS LLC | $3,225 | Research payment | Cash or cash equivalent | STUDY OF AG-270 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA WITH MTAP LOSS | 2021 | |
| 2021-07-26 | SERVIER PHARMACEUTICALS LLC | $2,340 | Research payment | Cash or cash equivalent | STUDY OF AG-270 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA WITH MTAP LOSS | 2021 | |
| 2021-07-26 | SEAGEN INC. | $2,162 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-07-26 | Indivior Inc. | $1,482 | Research payment | In-kind items and services | SUBLOCADE Drug, OUD | LONG-ACTING BUPRENORPHINE VS. NALTREXONE OPIOID TREATMENTS IN CJS-INVOLVED ADULTS | 2021 |
| 2021-07-26 | AstraZeneca Pharmaceuticals LP | $104 | Charitable Contribution | Cash or cash equivalent | 2021 | ||
| 2021-07-22 | Arrow International, Inc. | $7,500 | Research payment | Cash or cash equivalent | Turnpike Catheter Device, INTERVENTIONAL ACCESS | CTO-PCI | 2021 |
| 2021-07-22 | Heron Therapeutics, Inc. | $425 | Research payment | Cash or cash equivalent | Drug | Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1) | 2021 |
| 2021-07-21 | SEAGEN INC. | $1,200 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2021 |
| 2021-07-21 | SEAGEN INC. | $750 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2021 |
| 2021-07-20 | PFIZER INC. | $1,430 | Research payment | In-kind items and services | A PHASE 2 12 WEEK ADAPTIVE OPEN LABEL SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND PHARMACOK | 2021 | |
| 2021-07-20 | AstraZeneca Pharmaceuticals LP | $104 | Charitable Contribution | Cash or cash equivalent | 2021 | ||
| 2021-07-20 | AstraZeneca Pharmaceuticals LP | $52 | Charitable Contribution | Cash or cash equivalent | 2021 | ||
| 2021-07-19 | AstraZeneca Pharmaceuticals LP | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-07-08 | AstraZeneca Pharmaceuticals LP | $26 | Charitable Contribution | Cash or cash equivalent | 2021 | ||
| 2021-07-07 | AstraZeneca Pharmaceuticals LP | $52 | Charitable Contribution | Cash or cash equivalent | 2021 | ||
| 2021-06-28 | TransMedics, Inc. | $3,500 | Research payment | Cash or cash equivalent | ORGAN CARE SYSTEM Device, DEVICE | DCD HEART CAP | 2021 |
| 2021-06-28 | TransMedics, Inc. | $1,981 | Research payment | Cash or cash equivalent | ORGAN CARE SYSTEM Device, DEVICE | DCD HEART | 2021 |
| 2021-06-28 | TransMedics, Inc. | $325 | Research payment | Cash or cash equivalent | ORGAN CARE SYSTEM Device, DEVICE | DCD HEART | 2021 |
| 2021-06-21 | Johnson & Johnson Health Care Systems Inc. | $65 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-06-18 | MAYNE PHARMA COMMERCIAL LLC | $12,780 | Research payment | Cash or cash equivalent | TOLSURA Drug, INFECTIOUS DISEASE | 2021 | |
| 2021-06-17 | SEAGEN INC. | $1,732 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-06-17 | Sage Therapeutics, LLC | $1,300 | Research payment | Cash or cash equivalent | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC | 2021 | |
| 2021-06-17 | Sage Therapeutics, LLC | $1,200 | Research payment | Cash or cash equivalent | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC | 2021 | |
| 2021-06-16 | SEAGEN INC. | $22,937 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2021 |
| 2021-06-16 | SEAGEN INC. | $1,800 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2021 |
| 2021-06-10 | Heron Therapeutics, Inc. | $1,151 | Research payment | Cash or cash equivalent | Zynrelef Drug, Postoperative Pain | Herniorrhaphy Study for Opioid Elimination | 2021 |
| 2021-06-09 | SEAGEN INC. | $24,919 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2021 |
| 2021-06-09 | VentureMed Group, Inc. | $250 | Research payment | Cash or cash equivalent | FLEX Vessel Prep System Device, Vascular | FLEX-AV Registry | 2021 |
| 2021-06-05 | Conformis, Inc. | $1,430 | Research payment | Cash or cash equivalent | iTotal CR Device, ORTHOPAEDIC KNEE IMPLANTS | iTotal 12-005 | 2021 |
| 2021-06-04 | SANOFI US SERVICES INC. | $53 | Charitable Contribution | Cash or cash equivalent | 2021 | ||
| 2021-06-03 | TransMedics, Inc. | $5,785 | Research payment | Cash or cash equivalent | ORGAN CARE SYSTEM Device, DEVICE | DCD HEART CAP | 2021 |
| 2021-06-01 | Orthofix Medical, Inc. | $1,700 | Research payment | Cash or cash equivalent | M6-C Device, Prosthesis, Intervertebral Disc | M6-C Post Approval Study (PAS)- CA-C004 | 2021 |
| 2021-05-28 | Conformis, Inc. | $11,830 | Research payment | Cash or cash equivalent | iTotal CR Device, ORTHOPAEDIC KNEE IMPLANTS | iTotal 12-005 | 2021 |
| 2021-05-27 | Stryker Corporation | $1,670 | Research payment | Cash or cash equivalent | SURPASS EVOLVE Device, FLOW DIVERTER | EVOLVE | 2021 |
| 2021-05-26 | Cardiovascular Systems Inc. | $1,500 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2021 |
| 2021-05-26 | SEAGEN INC. | $390 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2021 |
| 2021-05-26 | SEAGEN INC. | $390 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2021 |
| 2021-05-25 | Heron Therapeutics, Inc. | $19,237 | Research payment | Cash or cash equivalent | Drug | Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1) | 2021 |
| 2021-05-24 | Johnson & Johnson Health Care Systems Inc. | $3,270 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-05-19 | VentureMed Group, Inc. | $7,475 | Research payment | Cash or cash equivalent | FLEX Vessel Prep System Device, Vascular | FLEX-AV Registry | 2021 |
| 2021-05-14 | Cardiovascular Systems Inc. | $2,470 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2021 |
| 2021-05-06 | Orthofix Medical, Inc. | $8,060 | Research payment | Cash or cash equivalent | M6-C Device, Prosthesis, Intervertebral Disc | Restore CLINICAL TRIAL CA-C002 (M6 IDE) | 2021 |
| 2021-05-04 | Eli Lilly and Company | $12 | Research payment | In-kind items and services | PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREA | 2021 | |
| 2021-04-29 | Intersect ENT, Inc. | $1,890 | Charitable Contribution | In-kind items and services | PROPEL Device, Otolaryngology (Ear, Nose, Throat) | 2021 | |
| 2021-04-28 | Arrow International, Inc. | $85,991 | Research payment | Cash or cash equivalent | Turnpike Catheter Device, INTERVENTIONAL ACCESS | CTO-PCI | 2021 |
| 2021-04-28 | SEAGEN INC. | $390 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2021 |
| 2021-04-28 | AngioDynamics, Inc. | $220 | Debt forgiveness | In-kind items and services | Asclera Drug, VIT | 2021 | |
| 2021-04-27 | SEAGEN INC. | $2,360 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-04-27 | SEAGEN INC. | $2,162 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-04-22 | Heron Therapeutics, Inc. | $24,241 | Research payment | Cash or cash equivalent | Drug | Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1) | 2021 |
| 2021-04-22 | Merit Medical Systems Inc | $2,680 | Debt forgiveness | Cash or cash equivalent | Embosphere Microspheres Device, Radiology | 2021 | |
| 2021-04-21 | Genentech USA, Inc. | $35,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Activase Biological, Metabolism & Primary Care | 2021 | |
| 2021-04-15 | Sage Therapeutics, LLC | $1,300 | Research payment | Cash or cash equivalent | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC | 2021 | |
| 2021-04-15 | Sage Therapeutics, LLC | $500 | Research payment | Cash or cash equivalent | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC | 2021 | |
| 2021-04-15 | Orthofix Medical, Inc. | $500 | Research payment | Cash or cash equivalent | M6-C Device, Prosthesis, Intervertebral Disc | M6-C Post Approval Study (PAS)- CA-C004 | 2021 |
| 2021-04-13 | Orthofix Medical, Inc. | $837 | Research payment | Cash or cash equivalent | M6-C Device, Prosthesis, Intervertebral Disc | M6-C Post Approval Study (PAS)- CA-C004 | 2021 |
| 2021-04-12 | Cardiovascular Systems Inc. | $156 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2021 |
| 2021-04-07 | SEAGEN INC. | $28,820 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2021 |
| 2021-04-07 | SEAGEN INC. | $260 | Research payment | Cash or cash equivalent | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2021 | |
| 2021-03-29 | SEAGEN INC. | $500 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2021 | |
| 2021-03-26 | TransMedics, Inc. | $4,420 | Research payment | Cash or cash equivalent | ORGAN CARE SYSTEM Device, DEVICE | DCD HEART CAP | 2021 |
| 2021-03-26 | Heron Therapeutics, Inc. | $500 | Research payment | Cash or cash equivalent | Drug | Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1) | 2021 |
| 2021-03-18 | Orthofix Medical, Inc. | $7,800 | Research payment | Cash or cash equivalent | M6-C Device, Prosthesis, Intervertebral Disc | M6-C Post Approval Study (PAS)- CA-C004 | 2021 |
| 2021-03-18 | Stryker Corporation | $781 | Long term medical supply or device loan | In-kind items and services | CHROMOPHARE F300 Device, COMMUNICATIONS | 2021 | |
| 2021-03-17 | Heron Therapeutics, Inc. | $5,015 | Research payment | Cash or cash equivalent | Drug | Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1) | 2021 |
| 2021-03-17 | Johnson & Johnson Health Care Systems Inc. | $661 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-03-12 | CARDIVA MEDICAL, INC. | $75,000 | Research payment | Cash or cash equivalent | Cardiva VASCADE 5F VCS Device, Devices | VASCADE Device Outcomes | 2021 |
| 2021-03-11 | TransMedics, Inc. | $6,305 | Research payment | Cash or cash equivalent | ORGAN CARE SYSTEM Device, DEVICE | DCD HEART | 2021 |
| 2021-03-04 | Heron Therapeutics, Inc. | $11,851 | Research payment | Cash or cash equivalent | Drug | Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1) | 2021 |
| 2021-03-04 | Medical Device Business Services, Inc. | $600 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-02-25 | TransMedics, Inc. | $17,550 | Research payment | Cash or cash equivalent | ORGAN CARE SYSTEM Device, DEVICE | DCD HEART | 2021 |
| 2021-02-25 | TransMedics, Inc. | $1,430 | Research payment | Cash or cash equivalent | ORGAN CARE SYSTEM Device, DEVICE | DCD HEART CAP | 2021 |
| 2021-02-24 | SEAGEN INC. | $15,632 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2021 |
| 2021-02-24 | SEAGEN INC. | $123 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2021 |
| 2021-02-22 | SEAGEN INC. | $390 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-02-21 | Regeneron Pharmaceuticals, Inc. | $100 | Charitable Contribution | Cash or cash equivalent | 2021 | ||
| 2021-02-18 | Heron Therapeutics, Inc. | $1,540 | Research payment | Cash or cash equivalent | Drug | Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1) | 2021 |
| 2021-02-10 | SEAGEN INC. | $390 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2021 |
| 2021-02-05 | MAYNE PHARMA COMMERCIAL LLC | $20,000 | Research payment | Cash or cash equivalent | TOLSURA Drug, INFECTIOUS DISEASE | 2021 | |
| 2021-02-03 | SEAGEN INC. | $24,292 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2021 |
| 2021-02-03 | SEAGEN INC. | $13,879 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2021 |
| 2021-02-03 | SEAGEN INC. | $260 | Research payment | Cash or cash equivalent | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2021 | |
| 2021-01-31 | Zimmer Biomet Holdings, Inc. | $11 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2021 | |
| 2021-01-28 | Heron Therapeutics, Inc. | $750 | Research payment | Cash or cash equivalent | Drug | Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1) | 2021 |
| 2021-01-27 | SEAGEN INC. | $1,500 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2021 |
| 2021-01-25 | SEAGEN INC. | $4,716 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-01-15 | SANOFI US SERVICES INC. | $100 | Charitable Contribution | Cash or cash equivalent | 2021 | ||
| 2021-01-14 | TransMedics, Inc. | $5,200 | Research payment | Cash or cash equivalent | ORGAN CARE SYSTEM Device, DEVICE | DCD HEART CAP | 2021 |
| 2021-01-07 | Heron Therapeutics, Inc. | $13,300 | Research payment | Cash or cash equivalent | Drug | Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1) | 2021 |
| 2021-01-01 | ClearPoint Neuro, Inc. | $13,836 | Long term medical supply or device loan | In-kind items and services | ClearPoint Neuro Workstation Device, Neurology | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In New Haven, CT, county South Central Connecticut Planning Region, CT, state Connecticut; placed by its city name.
| Measure | Place (city or town) New Haven, CT | County South Central Connecticut Planning Region, CT | State Connecticut |
|---|---|---|---|
| Population B01003 | 134,349 | 570,598 | 3,624,508 |
| Population, 2020 census P1 | 134,023 | - | 3,605,944 |
| Median age B01002 | 31.9 | 40.2 | 41.1 |
| Under 18 B01001 | 21.3% | 19.6% | 20.2% |
| 65 and over B01001 | 11.8% | 18.6% | 18.5% |
| Households B11001 | 54,773 | 230,673 | 1,434,007 |
| Foreign born B05002 | 18.0% | 13.7% | 15.7% |
| Median household income B19013 | $56,851 | $88,197 | $95,781 |
| Median family income B19113 | $68,668 | $115,384 | $122,706 |
| Per capita income B19301 | $36,242 | $49,766 | $55,915 |
| Poverty rate B17001 | 23.9% | 11.4% | 10.0% |
| Unemployment rate B23025 | 8.4% | 6.0% | 5.6% |
| Civilian labor force B23025 | 69,528 | 307,607 | 1,959,490 |
| Mean commute (minutes) B08013 | 21.5 | 23.5 | 26.5 |
| Bachelor's degree or higher B15003 | 38.9% | 42.0% | 42.5% |
| Housing units B25001 | 60,333 | 248,267 | 1,541,822 |
| Owner-occupied B25003 | 28.4% | 60.5% | 66.5% |
| Renters B25003 | 71.6% | 39.5% | 33.5% |
| Median home value B25077 | $287,100 | $353,100 | $366,900 |
| Median gross rent B25064 | $1,488 | $1,525 | $1,488 |
| White, not Hispanic B03002 | 30.0% | 58.5% | 61.9% |
| Black B03002 | 27.6% | 13.0% | 9.8% |
| Hispanic or Latino B03002 | 31.0% | 19.5% | 18.3% |
| Asian B03002 | 5.2% | 4.5% | 4.7% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.1% |
Economy now FRED unemployment 5.1% in Sep 2026 (4.2% a year earlier); per capita personal income $102,307 in 2025, up 33% in five years (+7.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in New Haven, CT.
Comments